Ebba Sohlberg

[MalmbergLab @MalmbergLab]

@ebba_sohlberg presenting our clinical cell therapy platform based on selective expansion of adaptive NK cells. Allogeneic Cell Therapy Summit, Boston

[Ebba Sohlberg @ebba_sohlberg]

@AmirHorowitz As it was also a GMP/practical consideration, we didn't test this systematically, we should. The feeling based on the importance of myeloid derived cytokines for adaptive expansions is ofc that there might be.

[Ebba Sohlberg @ebba_sohlberg]

@ScientistTess @MalmbergLab Thanks Tessa 😊😊

[Ebba Sohlberg @ebba_sohlberg]

@DjaoudZ @MalmbergLab Hi Zakia! As the protocol is intended for GMP manufacturing, a CD3/CD19 depletion is preferable as this is a one-step CliniMacs standard procedure (so cheaper and easier than CD56 enrichment). But expanding from isolated NK works too!

[MalmbergLab @MalmbergLab]

Selective expansion of adaptive NK cells from “superdonors”. This paper describes the pre-clinical evaluation, scale-up and GMP transfer activities paving the way for our next NK cell therapy trial. Team effort led by @AlvaroHaroun and @ebba_sohlberg with lots of collaborators.

[Ebba Sohlberg @ebba_sohlberg]

@BarbaraLKee @malmberglab @BarbaraLKee @AlinePfefferle In our 7-day IL-15 driven proliferation model, rapidly dividing cells have increased Ki-67, and enter the cell cycle with higher levels in G0/1 each time.

[Nature News & Views @NatureNV]

Antigen-specific immunotherapy using peptide-coated nanoparticles (£) https://t.co/d4PqiIXPqD

[Ebba Sohlberg @ebba_sohlberg]

https://t.co/SSC9FgSeMZ